Enzo Biochem ROA 2010-2022 | ENZ

Current and historical return on assets (ROA) values for Enzo Biochem (ENZ) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Enzo Biochem ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-04-30 $-0.01B $0.10B -6.44%
2022-01-31 $0.00B $0.11B 0.00%
2021-10-31 $0.01B $0.11B 4.46%
2021-07-31 $0.01B $0.11B 6.17%
2021-04-30 $0.00B $0.11B 0.88%
2021-01-31 $-0.01B $0.11B -9.67%
2020-10-31 $-0.02B $0.11B -18.26%
2020-07-31 $-0.03B $0.11B -24.63%
2020-04-30 $-0.03B $0.12B -26.67%
2020-01-31 $0.00B $0.12B 0.87%
2019-10-31 $0.00B $0.13B 0.93%
2019-07-31 $0.00B $0.11B 2.99%
2019-04-30 $0.00B $0.11B 2.02%
2019-01-31 $-0.02B $0.09B -23.59%
2018-10-31 $-0.02B $0.09B -15.65%
2018-07-31 $-0.01B $0.10B -10.38%
2018-04-30 $-0.01B $0.11B -4.65%
2018-01-31 $-0.00B $0.11B -1.85%
2017-10-31 $-0.00B $0.11B -1.86%
2017-07-31 $-0.00B $0.11B -1.86%
2017-04-30 $0.03B $0.11B 31.26%
2017-01-31 $0.03B $0.11B 31.68%
2016-10-31 $0.04B $0.11B 42.22%
2016-07-31 $0.05B $0.11B 52.48%
2016-04-30 $0.02B $0.08B 22.74%
2016-01-31 $0.02B $0.08B 22.70%
2015-10-31 $0.01B $0.07B 7.66%
2015-07-31 $-0.00B $0.07B -4.80%
2015-04-30 $-0.01B $0.06B -22.76%
2015-01-31 $-0.01B $0.06B -17.60%
2014-10-31 $-0.01B $0.06B -17.89%
2014-07-31 $-0.01B $0.06B -16.60%
2014-04-30 $-0.01B $0.06B -16.95%
2014-01-31 $-0.02B $0.06B -27.71%
2013-10-31 $-0.02B $0.06B -30.38%
2013-07-31 $-0.02B $0.06B -30.89%
2013-04-30 $-0.04B $0.06B -67.19%
2013-01-31 $-0.04B $0.06B -54.42%
2012-10-31 $-0.04B $0.07B -45.92%
2012-07-31 $-0.04B $0.07B -41.30%
2012-04-30 $-0.02B $0.10B -14.71%
2012-01-31 $-0.01B $0.10B -13.27%
2011-10-31 $-0.02B $0.10B -14.75%
2011-07-31 $-0.01B $0.11B -11.69%
2011-04-30 $-0.02B $0.11B -13.30%
2011-01-31 $-0.02B $0.11B -15.75%
2010-10-31 $-0.02B $0.12B -18.60%
2010-07-31 $-0.02B $0.12B -18.78%
2010-04-30 $-0.02B $0.12B -17.32%
2010-01-31 $-0.02B $0.13B -15.85%
2009-10-31 $-0.02B $0.13B -14.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.120B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $160.059B 9.71
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.535B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Myovant Sciences (MYOV) United Kingdom $1.600B 0.00
Emergent Biosolutions (EBS) United States $1.482B 8.59
Zymeworks (ZYME) Canada $0.390B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00